Search for content, post, videos

SenzaGen appoints US Business Development Director and establishes a wholly-owned subsidiary


The company is strengthening its presence in the US market through a recruitment of Dr. Joshua J. Schmidt as Business Development Director at SenzaGen Inc.

The appointment represents a further expansion of the company’s commercial organization and an increasing focus on establishing collaborations with both licensees and distributors, in accordance with SenzaGen’s recently communicated financial targets.

A wholly-owned subsidiary

In parallel with the recruitment, SenzaGen Inc also becomes a wholly-owned subsidiary, offering additional possibilities for steering the commercial strategy in the US. SenzaGen is focusing on the chemical, cosmetics, pharmaceutical and medical device markets for global commercialization of the in vitro platform GARD.


“The US is a priority market, and through the recruitment of Joshua J. Schmidt, we are strengthening our organisation by adding significant network, knowledge and insight into the US market, which contributes to achieving our financial targets,” says Anki Malmborg Hager, CEO of SenzaGen.

Business and science

Joshua J. Schmidt has extensive business and scientific experience from 3M, Medtronic and Bruker Daltonics, most recently as Senior Account Executive for a US-based CRO, Pace Analytical Life Sciences, where he worked with testing of pharmaceutical products and medical devices in the US.

“SenzaGen’s technology is impressive and has true potential to significantly and positively impact the chemical and life science industries. I am excited to join SenzaGen at this time because I see great opportunity and potential for growth in the US and globally for GARD”, says Joshua J. Schmidt, Business Development Director at SenzaGen Inc.